Ramdan Hours:
Sun - Thu
9.30 AM - 2.30 PM
Iftar in --:--:--
🌙 Maghrib: --:--
Image from Google Jackets

Nanocarriers as a tool for the dermal delivery of an antifungal agent / Aya Hussein Sayed Metwally, (Bachelor of Pharmaceutical Sciences, Faculty of Pharmacy, Ain shams University Demonstrator at dept. of Pharmaceutics & Pharmaceutical Technology), supervision of Prof. Dr. Omaima A. Sammour, (Professor of Pharmaceutics and Industrial Pharmacy-Faculty of Pharmacy- Ain Shams University), Prof. Dr. Mona Ibrahim Abdeltawab Elassal, (Professor of Pharmaceutics and Industrial Pharmacy- Faculty of Pharmacy- Future university), Dr. Mona Mohamed Ahmed Abdel-Mottaleb, (Associate professor of Pharmaceutics and Industrial Pharmacy-Faculty of Pharmacy- Ain Shams University).

By: Material type: TextTextLanguage: English Summary language: Arabic Publisher: 2021Description: 234 pages, 5 pages : illustrations (some color) ; 24 cmContent type:
  • text
Media type:
  • unmediated
Carrier type:
  • volume
Other title:
  • الحاملات النانوية كوسيلة لإنتقال دواء مضاد للفطريات عبر الجلد [Added title page title]
Subject(s): DDC classification:
  • 615.19 M.A.N 22
Online resources: Dissertation note: Thesis (M.Sc.)-Ain Shams university, Faculty of pharmacy, Department of Pharmaceutics, 2021. Abstract: Renal allograft survival requires multiple immunosuppressive drugs. This strategy may lead to gastric complications that necessitate gastro-protective medications, notably, proton pump inhibitors (PPI). This study aimed to compare the influence of pantoprazole and esomeprazole on serum cyclosporine trough levels (C0) in renal transplant recipients (RTR). A prospective, parallel, open-label trial was conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain trough concentrations of 100 to 150 μg/L, mycophenolate mofetil (MMF) 750 mg q12 hour and prednisolone at 5 mg daily at Nasser Institute, Cairo, Egypt from January to September 2016. Patients were randomized into the esomeprazole group (25) or pantoprazole group (22) receiving the same dose (40 mg once daily). The study outcomes included clinical signs of rejection and renal function decline, assessed by elevations in serum creatinine, caused by cyclosporine level variations in either of the two study groups. Renal function, C0 and CBC measurements were measured at baseline and monthly for 6 months. The mean C0 values were higher in the pantoprazole group than in the esomeprazole group in the sixth month only (P = .007). Serum creatinine level was lower in the sixth month than at baseline in the esomeprazole group (P = .004). There were no signs of rejection biochemical or clinical in any of the study groups. In conclusion, PPIs should be used with caution and doses should be titrated to reach the C0 targets in RTR, which is of more importance in pantoprazole than esomeprazole to avoid C0 level elevation or decline affecting the allograft function
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode
Thesis Thesis Main library C3 THESIES Pharmacy ( Pharmaceutical Technology ) 615.19 M.A.N (Browse shelf(Opens below)) Not for loan 00016499

supervision of Prof. Dr. Omaima A. Sammour, (Professor of Pharmaceutics and Industrial Pharmacy-Faculty of Pharmacy- Ain Shams University), Prof. Dr. Mona Ibrahim Abdeltawab Elassal, (Professor of Pharmaceutics and Industrial Pharmacy- Faculty of Pharmacy- Future university), Dr. Mona Mohamed Ahmed Abdel-Mottaleb, (Associate professor of Pharmaceutics and Industrial Pharmacy-Faculty of Pharmacy- Ain Shams University).

Thesis (M.Sc.)-Ain Shams university, Faculty of pharmacy, Department of Pharmaceutics, 2021.

Includes bibliographical references.

Renal allograft survival requires multiple immunosuppressive drugs. This strategy
may lead to gastric complications that necessitate gastro-protective medications,
notably, proton pump inhibitors (PPI). This study aimed to compare the influence
of pantoprazole and esomeprazole on serum cyclosporine trough levels (C0) in
renal transplant recipients (RTR). A prospective, parallel, open-label trial was
conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain trough
concentrations of 100 to 150 μg/L, mycophenolate mofetil (MMF) 750 mg
q12 hour and prednisolone at 5 mg daily at Nasser Institute, Cairo, Egypt from
January to September 2016. Patients were randomized into the esomeprazole
group (25) or pantoprazole group (22) receiving the same dose (40 mg once daily).
The study outcomes included clinical signs of rejection and renal function
decline, assessed by elevations in serum creatinine, caused by cyclosporine level
variations in either of the two study groups. Renal function, C0 and CBC measurements were measured at baseline and monthly for 6 months. The mean C0
values were higher in the pantoprazole group than in the esomeprazole group in
the sixth month only (P = .007). Serum creatinine level was lower in the sixth
month than at baseline in the esomeprazole group (P = .004). There were no
signs of rejection biochemical or clinical in any of the study groups. In conclusion,
PPIs should be used with caution and doses should be titrated to reach the C0 targets in RTR, which is of more importance in pantoprazole than esomeprazole to
avoid C0 level elevation or decline affecting the allograft function

Text in English, abstracts in English and Arabic.

There are no comments on this title.

to post a comment.